Ionica Sciences™ has developed a new technology platform to meet urgent needs for a variety of clinical diagnostics such as Lyme disease, COVID, mosquito-borne diseases and STIs.
Our first test, IonLyme™, specifically addresses Lyme disease, the fastest growing vector borne disease in the United States.
IonLyme is Designed for Early Detection
Lyme disease is most easily cured during its early stages and becomes both difficult and expensive to treat in later stages, leading to severe health consequences. Current diagnostics test for immune response, which is difficult to detect until 30 days after the initial exposure, causing over half of early Lyme disease cases to be missed.
Rather than looking for an immune response, allowing Lyme disease to essentially “hide” during the first 30 days, IonLyme directly detects early and active Lyme disease by testing serum samples for Outer Surface protein A (“OspA”). OspA is present only in active Lyme disease infections, making it a superior diagnostic target for clinical decision making.
IonLyme Increases Testing Accuracy
With Lyme disease “hiding” from the immune system during its early stages, it is no wonder that current diagnostic tests are only demonstrating 50% accuracy in catching early stage Lyme.
IonLyme is different. It detects a protein in blood that is only present in early Lyme disease. Pre-clinical testing shows an accuracy of over 90%, which will dramatically reduce the number of advanced Lyme disease cases every year.
IonLyme Identifies Cases of Reinfection
A person exposed to Lyme disease can circulate antibodies for up to a decade. With current diagnostics testing only for an immune response, these tests become useless for detecting a new infection in a patient that was diagnosed with Lyme in years past.
By detecting OspA, which is only present in the blood during an active infection, IonLyme is capable of detecting a potential reinfection, helping to determine if a person is cured of active Lyme.
The Problem with Current Lyme Disease Diagnostics is Clear
“The biggest problem is that there is no way to test, unequivocally, for the presence of the bacteria that cause the disease.”
“There are no accurate diagnostic tests, no vaccines, and whatever treatment is provided is often inadequate.”
”Lyme disease is the most common tick-borne disease in the United States. Each year, approximately 30,000 cases of Lyme disease are reported in the country. However, the Centers for Disease Control and Prevention (CDC) believes that the actual number of Americans who get Lyme disease each year may be closer to 300,000.”
IonLyme is not yet available for sale, and these statements have not been evaluated by FDA.
Ionica Sciences is offering securities under Regulation CF and Rule 506(c) of Regulation D through SI Securities, LLC (“SI Securities”). The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained at https://www.seedinvest.com/ionica.sciences.inc
Headquartered Inside McGovern Family Center for Venture Development in the Life Sciences
Cornell University, 413 Weill Hall, Ithaca, NY 14853
McGovern Family Center for Venture Development in the Life Sciences
413 Weill Hall
Ithaca, NY 14853